Citigroup
CUE icon

Citigroup’s Cue Biopharma CUE Stock Holding History

Citigroup’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$95 – 6136
2025
Q3 		$95 Buy
+4
New +$94 ﹤0.01% 5813
2025
Q1 		– Sell
-1
Closed -$47 – 5664
2024
Q4 		$47 Hold
1
– – ﹤0.01% 5717
2024
Q3 		$33 Sell
1
-167
-99% -$3.62K ﹤0.01% 5581
2024
Q2 		$6.26K Sell
168
-34
-17% -$1.68K ﹤0.01% 5225
2024
Q1 		$11.5K Buy
202
+16
+9% +$1.13K ﹤0.01% 5169
2023
Q4 		$14.7K Buy
186
+185
+18,500% +$13.2K ﹤0.01% 5088
2023
Q3 		$80 Sell
1
-342
-100% -$33.4K ﹤0.01% 5455
2023
Q2 		$37.6K Buy
+343
New +$40.3K ﹤0.01% 4782
2022
Q3 		– Sell
-10
Closed -$1K – 5904
2022
Q2 		$1K Sell
10
-57
-85% -$6.67K ﹤0.01% 6000
2022
Q1 		$10K Sell
67
-2,606
-97% -$553K ﹤0.01% 5523
2021
Q4 		$907K Buy
2,673
+1,733
+184% +$670K ﹤0.01% 3355
2021
Q3 		$411K Sell
940
-1,831
-66% -$639K ﹤0.01% 3746
2021
Q2 		$968K Buy
2,771
+296
+12% +$115K ﹤0.01% 3257
2021
Q1 		$906K Buy
2,475
+2,275
+1,138% +$936K ﹤0.01% 3057
2020
Q4 		$75K Buy
200
+119
+147% +$47.5K ﹤0.01% 5761
2020
Q3 		$36K Sell
81
-1,453
-95% -$837K ﹤0.01% 5793
2020
Q2 		$1.13M Buy
1,534
+1,332
+659% +$965K ﹤0.01% 3437
2020
Q1 		$86K Buy
202
+67
+50% +$32.5K ﹤0.01% 5471
2019
Q4 		$65K Sell
135
-343
-72% -$108K ﹤0.01% 6105
2019
Q3 		$121K Sell
478
-86
-15% -$20.7K ﹤0.01% 5528
2019
Q2 		$152K Buy
564
+4
+0.7% +$995 ﹤0.01% 5504
2019
Q1 		$130K Sell
560
-13
-2% -$2.47K ﹤0.01% 5499
2018
Q4 		$80K Sell
573
-221
-28% -$40.1K ﹤0.01% 5843
2018
Q3 		$216K Buy
794
+77
+11% +$22.2K ﹤0.01% 5169
2018
Q2 		$255K Sell
717
-1,152
-62% -$458K ﹤0.01% 4803
2018
Q1 		$788K Buy
+1,869
New +$852K ﹤0.01% 3487

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Citigroup's CUE Position: Q4 2025 in Review

Citigroup sold out of Cue Biopharma (CUE) in Q4 2025, closing a stake of 4 shares — an estimated $95 sold.

Citigroup first reported a position in CUE in Q1 2018 and held it in 26 quarters. The position peaked at $1.13M in Q2 2020. 47 funds tracked by Wall St. Rank hold CUE as of Q4 2025.

  • Citigroup reported no remaining Cue Biopharma position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 4 Cue Biopharma shares in Q4 2025, an estimated $95.
  • Citigroup first reported a position in Cue Biopharma in Q1 2018 and held it in 26 quarters.
  • Citigroup's Cue Biopharma position peaked at $1.13M in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.